As we kick off the new year, here’s a look at some of the headlines in North Carolina biotech and tech news from the holiday break.
—Chimerix’s (NASDAQ: CMRX) lead antiviral drug candidate failed a late-stage clinical trial of its... Read more »
It was the year of drug pricing, fantasy-sports and Uber regulations, and countless cyber and terror attacks. It was a year when initial public offerings were few and far between for technology companies, and the biotech window may have closed as... Read more »
“Synthetic biology” has always been a puzzling term to me. Prosthetic limbs are synthetic. Knee replacements are synthetic. Splicing the gene from one organism into another, a practice that began in the 1970s and gave rise to the biotechnology industry, is... Read more »
Thong Le is the CEO of Accelerator, a Seattle biotech venture fund and incubator more than a decade old. Le took over in early 2014 and is overseeing a cross-country expansion. A second Accelerator facility opened with fanfare in New York... Read more »
A drug meant to fight a broad spectrum of viruses has failed a key study in the prevention of a potentially fatal infection in transplant patients, crushing the stock price of the drug’s developer, Chimerix.
Durham, NC-based Chimerix (NASDAQ: CMRX)... Read more »
Every three months, Oxford Dictionaries releases its new entries, and modern language mavens everywhere have a field day.
A few of my favorites from the summer update: weak sauce, microaggression, cupcakery, and at the risk of perpetuating... Read more »
When OurCrowd founder and CEO Jonathan Medved gives a talk about crowdfunding, as he did at the recent Stocktoberfest conference in San Diego, there is one particular slide in his deck that is something of a show stopper.
Medved says it... Read more »